<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04629794</url>
  </required_header>
  <id_info>
    <org_study_id>SS-OS-1802</org_study_id>
    <nct_id>NCT04629794</nct_id>
  </id_info>
  <brief_title>The OsteoStrand Plus Deformity Study</brief_title>
  <official_title>The OsteoStrand Plus Deformity Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SeaSpine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SeaSpine, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical study evaluating outcomes for patients with spinal deformity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A clinical study evaluating deformity patients treated with Demineralized Bone Matrix as&#xD;
      compared to patients treated with Bone Morphogenetic Protein.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of fusion for the demineralized bone matrix cohort vs bone morphogenic protein cohort</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of spinal levels in the demineralized bone matrix cohort vs bone morphogenic protein cohort achieving fusion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Spinal Fusion</condition>
  <arm_group>
    <arm_group_label>Demineralized Bone Matrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bone Morphogenic Protein</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterolateral Lumbar Fusion with Demineralized Bone Fibers</intervention_name>
    <description>Posterolateral Lumbar Fusion with Demimeralized Bone Fibers</description>
    <arm_group_label>Demineralized Bone Matrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Posterolateral Lumbar Fusion with Bone Morphogenic Protein</intervention_name>
    <description>Posterolateral Lumbar Fusion with Bone Morphogenic Protein</description>
    <arm_group_label>Bone Morphogenic Protein</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -â‰¥18 years of age&#xD;
&#xD;
          -  Indicated for deformity correction surgery&#xD;
&#xD;
          -  Require spinal fusion at four or more levels&#xD;
&#xD;
          -  Are willing to return for follow-up visits&#xD;
&#xD;
          -  Willing to sign the Informed Consent Forms&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  history of alcohol or drug abuse&#xD;
&#xD;
          -  Corticosteroid use&#xD;
&#xD;
          -  Fever or leukocytosis&#xD;
&#xD;
          -  Systemic infection&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Elevation of white blood cell count&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Disease of bone metabolism&#xD;
&#xD;
          -  Unsuitable or insufficient bone support&#xD;
&#xD;
          -  Skeletal immaturity&#xD;
&#xD;
          -  Prior fusion&#xD;
&#xD;
          -  Use of steroids, immune suppressants, osteoporosis medications&#xD;
&#xD;
          -  Use of internal bone stimulators&#xD;
&#xD;
          -  Institutionalized or a prisoner&#xD;
&#xD;
          -  Undergoing (Undergone) a worker's compensation case&#xD;
&#xD;
          -  Pregnancy (includes women who are currently pregnant, lactating or wishing to become&#xD;
             pregnant during the study duration)&#xD;
&#xD;
          -  Participation in another research study involving another implant, product or drug&#xD;
             that may affect the outcomes of this clinical study within the last 30 days, or&#xD;
             planned during this clinical study&#xD;
&#xD;
          -  Any other condition that the Investigator determines is unacceptable for enrollment&#xD;
             into this clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sonoran Spine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Biodun Adeniyi, MBBS, MS</last_name>
    <phone>4805973138</phone>
    <email>biodun@sonoranspine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sonoran Spine</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Biodun Adeniyi, MBBS, MS</last_name>
      <phone>480-597-3138</phone>
      <email>biodun@sonoranspine.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

